Reprint of: Epidemiological serosurvey of Hepatitis B in China-Declining HBV prevalence due to Hepatitis B vaccination

Vaccine

Volumn 31, Issue S9, 2013, Pages

  Liang, Xiaofeng ^a   Bi, Shengli ^a   Yang, Weizhong ^a   Wang, Longde ^b   Cui, Gang ^b   Cui, Fuqiang ^a   Zhang, Yong ^a   Liu, Jianhua ^a   Gong, Xiaohong ^a   Chen, Yuansheng ^a   Wang, Fuzhen ^a   Zheng, Hui ^a   Wang, Feng ^a   Guo, Jing ^a   Jia, Zhiyuan ^a   Ma, Jingchen ^c   Wang, Huaqing ^a   Luo, Huiming ^a   Li, Li ^a   Jin, Shuigao ^a   Hadler, Stephen C ^d   Wang, Yu ^a   more..

^a CHINESE CENTER FOR DISEASE CONTROL AND PREVENTION   (China)

^b BEIJING HOSPITAL   (China)

^c Hebei Provincial Center for Disease Control and Prevention   (China)

^d WHO Representative Office in China   (China)

Author keywords

Hepatitis B; Immunization; Serosurvey

Indexed keywords

HEPATITIS B SURFACE ANTIGEN; HEPATITIS B VACCINE;

ADOLESCENT; ADULT; ARTICLE; BLOOD SAMPLING; CHILD; CHINA; ETHNIC GROUP; FEMALE; HEALTH PROGRAM; HEALTH SURVEY; HEPATITIS B; HUMAN; IMMUNIZATION; INFANT; MAJOR CLINICAL STUDY; MALE; PREVALENCE; PRIORITY JOURNAL; VACCINATION;

EID: 84892393046     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2013.08.012     Document Type: Article

References (31)

1. Xia G.L., Liu C.B., Cao H.L., Bi S.L., Zhan M.Y., Su C.A., et al. Prevalence of hepatitis B and C virus infections in the general Chinese population. Results from a nationwide cross-sectional seroepidemiologic study of hepatitis A, B, C, D and E virus infections in China, 1992. Int Hepatol Commun 1996, 5:62-73.
2. Dai Z.C., Qi G.M. Seroepidemiological Survey in Chinese population (part one), 1992-1995. Beijing. Sci Tech Exp 1996, 39-59.
3. Zhuang H. Epidemiology of hepatitis. Chin J Vaccines Immun 2004, 10(3):180-181.
4. He J., Gu D.F., Wu X.G., Kristi R., Duan X.F., Yao C.H., et al. Major causes of death among men and women in China. N Engl J Med 2005, 353:1124-1134.
5. Perz J.F., Armstrong G.L., Farrington L.A., Hutin Y.J.F., Bell B.P. The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. J Hepatol 2006, 45:529-538.
6. Evans A.A., Chen G., Ross E.A., Shen F.M., Lin W.Y., Thomas L.W., et al. Eight-year follow-up of the 90,000-person Haimen City cohort: I. Hepatocellular carcinoma mortality, risk factors, and gender differences. Cancer Epidemiol, Biomarkers Prev 2002, (11):369-376.
7. Zhu X., Zhang X., Wang L. National EPI vaccination and hepatitis B vaccine coverage rate and the related factors: Results from the 1999 nationwide survey. Chin J Vacc Immun 2000, 6(4):193-197.
8. Ministry of Health, National EPI review in 2004. Beijing, Chinese people's health express; 2005. p. 24.
9. Cui F.Q., Wang X.J., Cao L., Liang X.F., Lu Y., Hu Y.S., et al. Progress in hepatitis B prevention through universal infant immunization - China, 1997-2006. MMWR 2007, 56(18):441-445.
10. Ministry of Health, China. 2006-2010 National guidelines for hepatitis B prevention and treatment; January 28, 2006.
11. CDC. Global progress toward universal childhood hepatitis B vaccination, 2003. MMWR 2003;52:868-70.
12. Yang G.H., Zhou M.G., Huang Z.J., et al. Study on the trend and disease burden of Injury deaths in Chinese population, 1991-2000. Chin J Epidemiol 2004, 25(3):192-198.
13. Yang G.H. Disease surveillance system selection in second stage and its representative. Chin J Epidemiol 1992, 1(13):197-201.
14. Chinese Center for Disease Control and Prevention. Guideline for chronic disease and high risk factors surveillance in China; August 2007.
15. Sun Z., Xu Y. Medical statistics (second edition), Beijing. Chin People's Health Exp 2006, 579-580.
16. Korn E., Graubard B. Examples of differing weighted and unweighted estimates from a sample survey. Am Statistician 1995, 49(August (3)):291.
17. Hyattsville, 2003 National Health Interview Survey (NHIS) Public Use Data Release, Division of Health Interview Statistics, National Center for Health Statistics, Centers for Disease Control and Prevention, U.S. Department of Health and Human Services; December, 2004. p. 8-9.
18. Chantala K, Blanchette D, Suchindran CM. Software to compute sampling weights for multilevel analysis. Carolina Population Center, UNC at Chapel Hill, Last Update; January 17, 2006.
19. Lohr S.L. Sampling: Design and analysis, Beijing. China Statistical Exp 2002, 245.
20. Euler G.L., Wooten K.G., Baughman A.L., Williams W.W. Hepatitis B surface antigen prevalence among pregnant women in urban areas: Implications for testing, reporting, and preventing perinatal transmission. Pediatrics 2003, 111:1192-1197.
21. Goldstein S.T., Zhou F.J., Hadler S., Bell B.B., Mast E.E., Margolis H.S., et al. A mathematical model to estimate global hepatitis B disease burden and vaccination impact. Int J Epidemiol 2005, 34:1329-1339.
22. Davaalkham D., Ojima T., Uehara R., Watanabe M., Oki I., Wiersma S., et al. Impact of the universal hepatitis B immunization program in Mongolia: achievements and challenges. J Epidemiol 2008, 17(3):69-75.
23. Ni Y.H., Huang L.M., Chang M.H., Yen C.J., Lu C.Y., Kao S.L., et al. Two decades of universal hepatitis B vaccination in Taiwan: impact and implication for future strategies. Gastroenterology 2007, 132(4):1287-1293.
24. Da Villa G., Romano L., Sepe A., Iorio R., Paribello N., Zappa A., et al. Impact of hepatitis B vaccination in a highly endemic area of south Italy and long-term duration of anti-HBs antibody in two cohorts of vaccinated individuals. Vaccine 2007, 25(16):3133-3136.
25. Madani T.A. Trend in incidence of hepatitis B virus infection during a decade of universal childhood hepatitis B vaccination in Saudi Arabia. Trans R Soc Trop Med Hyg 2007, 101(3):278-283.
26. Ng K.P., Saw T.L., Baki A. Impact of the expanded program of immunization against Hepatitis B infection in school children in Malaysia. Med Microbiol Immunol 2005, 194(3):163-168.
27. Gong J., Li R.C., Yang J.Y., Li Y.P., Chen X.R., Xu Z.Y., et al. Long-term efficacy of infant hepatitis B immunization program. Chin J. Hepatol 2003, 11:203-205.
28. Gong X.H., Wang F.Z., Li H., Liu L.R., Li Y.H., Wang B.L., et al. Observation on effects of hepatitis B vaccine immunization for 12 years in children in Beijing. Zhonghua Yu Fang Yi Xue Za Zhi 2005, 39:265-268.
29. Wu W.S., Sun C.M., Jiang M.B. Long-term effect of plasma derived vaccine in prevention of hepatitis B (Eigthteen years followup study). Chin J Vacc Immunization 2005, 11:204-207.
30. Liang X.F., Bi Sl, Yang W.Z., Wang L.D., Cui G., Cui F.Q., et al. Evaluation of the impact of Hepatitis B vaccination among Children born between 1992 and 2005 in China. J infect Dis 2009, 200(1):39-47.
31. Chang M.H., Chen J.C., Lei M.S., Hsu H.M., Wu T.C., Kong M.S., et al. Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children. N Engl J Med 1997, 336:1855-1859.